Amgen’s Nplate Approved With Restricted Access Program
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of the first platelet producer includes a REMS with a patient and physician tracking program.
You may also be interested in...
Intas Has India’s First Romiplostim Biosimilar
India’s Intas Pharmaceuticals has announced the launch of romiplostim in India to treat a rare blood disorder that will significantly reduce treatment costs.
GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date
GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date